PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23386687-0	2013	Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis.	INK128	77-84	mechanistic target of rapamycin kinase	Mus musculus	45-49	
23386687-7	2013	Marked reduction in activation of mTOR complex (mTORC)1 and blockade of cell growth was seen with both drugs, whereas only MLN0128 treatment had effects in blocking mTORC2 and 4EBP1 phosphorylation.	INK128	123-130	CREB regulated transcription coactivator 2	Mus musculus	165-171	
23386687-7	2013	Marked reduction in activation of mTOR complex (mTORC)1 and blockade of cell growth was seen with both drugs, whereas only MLN0128 treatment had effects in blocking mTORC2 and 4EBP1 phosphorylation.	INK128	123-130	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	176-181	
23386687-10	2013	Differences in side-effect profiles might make MLN0128 more attractive for treatment of patients with TSC-related tumors, but will require additional study in humans.	INK128	47-54	TSC complex subunit 1	Mus musculus	102-105